Listeria Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Condition:   2nd-line, 3rd-line and Greater Metastatic Pancreatic CancerInterventions:   Biological: GVAX Pancreas Vaccine;   Biological: CRS-207;   Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib;   Drug: cyclophosphamideSponsor:   Aduro BioTech, Inc.Recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 6, 2013 Category: Research Source Type: clinical trials

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Condition:   2nd-line, 3rd-line and Greater Metastatic Pancreatic CancerInterventions:   Biological: GVAX Pancreas Vaccine;   Biological: CRS-207;   Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib;   Drug: cyclophosphamideSponsor:   Aduro BioTech, Inc.Recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2013 Category: Research Source Type: clinical trials

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Condition:   2nd-line, 3rd-line and Greater Metastatic Pancreatic CancerInterventions:   Biological: GVAX Pancreas Vaccine;   Biological: CRS-207;   Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib;   Drug: cyclophosphamideSponsor:   Aduro BioTech, Inc.Recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2013 Category: Research Source Type: clinical trials

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Condition:   2nd-line, 3rd-line and Greater Metastatic Pancreatic CancerInterventions:   Biological: GVAX Pancreas Vaccine;   Biological: CRS-207;   Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib;   Drug: cyclophosphamideSponsor:   Aduro BioTech, Inc.Recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2013 Category: Research Source Type: clinical trials

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Condition:   2nd-line, 3rd-line and Greater Metastatic Pancreatic CancerInterventions:   Biological: GVAX Pancreas Vaccine;   Biological: CRS-207;   Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib;   Drug: cyclophosphamideSponsor:   Aduro BioTech, Inc.Recruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2013 Category: Research Source Type: clinical trials

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Condition:   2nd-line, 3rd-line and Greater Metastatic Pancreatic CancerInterventions:   Biological: GVAX Pancreas Vaccine;   Biological: CRS-207;   Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib;   Drug: cyclophosphamideSponsor:   Aduro BioTech, Inc.Recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2013 Category: Research Source Type: clinical trials